Wild-Type MIC Distributions and Epidemiological Cutoff Values for Caspofungin and Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document)
Open Access
- 1 June 2011
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (6) , 2855-2859
- https://doi.org/10.1128/aac.01730-10
Abstract
Clinical breakpoints have not been established for mold testing. Epidemiologic cutoff values (ECVs) are available for six Aspergillus spp. and the triazoles, but not for caspofungin. Wild-type (WT) minimal effective concentration (MEC) distributions (organisms in a species-drug combination with no acquired resistance mechanisms) were defined in order to establish ECVs for six Aspergillus spp. and caspofungin. The number of available isolates was as follows: 1,691 A. fumigatus, 432 A. flavus, 192 A. nidulans, 440 A. niger, 385 A. terreus, and 75 A. versicolor isolates. CLSI broth microdilution MEC data gathered in five independent laboratories in Canada, Europe, and the United States were aggregated for the analyses. ECVs expressed in μg/ml that captured 95% and 99% of the modeled wild-type population were for A. fumigatus 0.5 and 1, A. flavus 0.25 and 0.5, A. nidulans 0.5 and 0.5, A. niger 0.25 and 0.25, A. terreus 0.25 and 0.5, and A. versicolor 0.25 and 0.5. Although caspofungin ECVs are not designed to predict the outcome of therapy, they may aid in the detection of strains with reduced antifungal susceptibility to this agent and acquired resistance mechanisms.Keywords
This publication has 30 references indexed in Scilit:
- Fungal echinocandin resistanceFungal Genetics and Biology, 2010
- Species Identification and Antifungal Susceptibility Patterns of Species Belonging to Aspergillus Section NigriAntimicrobial Agents and Chemotherapy, 2009
- Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β- d -Glucan Synthase: Implication for the Existing Susceptibility BreakpointAntimicrobial Agents and Chemotherapy, 2009
- Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility TestingAntimicrobial Agents and Chemotherapy, 2009
- In Vitro Activities of Various Antifungal Drugs against Aspergillus terreus : Global Assessment Using the Methodology of the European Committee on Antimicrobial Susceptibility TestingAntimicrobial Agents and Chemotherapy, 2009
- Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans : Implications for Interpretive BreakpointsAntimicrobial Agents and Chemotherapy, 2009
- Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata InfectionAntimicrobial Agents and Chemotherapy, 2008
- Establishing In Vitro-In Vivo Correlations for Aspergillus fumigatus : the Challenge of Azoles versus EchinocandinsAntimicrobial Agents and Chemotherapy, 2008
- Mutations in the fks1 Gene in Candida albicans , C. tropicalis , and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility TestingAntimicrobial Agents and Chemotherapy, 2008
- A Ser678Pro Substitution in Fks1p Confers Resistance to Echinocandin Drugs in Aspergillus fumigatusAntimicrobial Agents and Chemotherapy, 2007